Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10115839 | 0.90 | TRPV1 (0.47) | MAPTL3MBTL1TRPV1KMT2AEPHX2 | |
| SCHEMBL10115576 | 0.89 | L3MBTL1 (0.61) | MAPTL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL10116174 | 0.87 | TRPV1 (0.47) | MAPTL3MBTL1TRPV1SMN1; SMN2KMT2A | |
| SCHEMBL10115716 | 0.87 | LMNA (0.46) | MAPTTRPV1SMN1; SMN2KMT2AEPHX2 | |
| SCHEMBL13204648 | 0.87 | EPHX2 (0.56) | TRPV1EPHX2 | |
| SCHEMBL10115587 | 0.86 | L3MBTL1 (0.49) | MAPTL3MBTL1SMN1; SMN2KMT2AHTR1A | |
| SCHEMBL10115836 | 0.85 | EPHX2 (0.47) | MAPTTRPV1EPHX2 | |
| SCHEMBL10115745 | 0.85 | SLC6A3 (0.47) | MAPTKMT2AEPHX2 | |
| SCHEMBL10115585 | 0.84 | SMN1; SMN2 (0.53) | MAPTL3MBTL1SMN1; SMN2HTR1AHTR1D | |
| SCHEMBL10115650 | 0.83 | POLB (0.57) | MAPTL3MBTL1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | MAPT 3602/4885L3MBTL1 3267/4885TRPV1 774/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | MAPT 3367/4885L3MBTL1 2541/4885TRPV1 534/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | MAPT 3683/4885L3MBTL1 3389/4885TRPV1 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.